Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

Phenylephrine Hydrochloride and Tropicamide, the active ingredients in Mydriasert, are mydriatic agents presented as an ophthalmic solution for ocular use. They produce pupil dilation to facilitate diagnostic eye examinations.

GNH USA supplies Mydriasert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU GMP standards and providing reliable cold‑chain logistics where required. It meets the specifications set by the European Medicines Agency for ophthalmic preparations.

Mydriasert, a combination mydriatic agent, is used to achieve pupil dilation during ophthalmic examinations. - Diagnostic eye examinations: provides rapid and sustained pupil dilation to allow detailed fundus and retinal imaging. - Pre‑operative ocular procedures: facilitates adequate pupil opening for cataract extraction, laser iridotomy and other intra‑ocular surgeries. - Glaucoma assessment: enables accurate measurement of intra‑ocular pressure and optic nerve evaluation after dilation. - Retinal disease monitoring: dilates the pupil to improve visualization of macular lesions, diabetic retinopathy and vascular abnormalities. - Uveitis evaluation: allows thorough inspection of the anterior and posterior segments in inflammatory eye conditions.

Mydriasert may cause ocular and systemic adverse reactions, most of which are mild and transient. Common Side Effects: - Transient ocular redness - Mild eye discomfort or stinging - Temporary blurred vision Serious or Rare Side Effects: - Acute angle‑closure glaucoma - Severe allergic reaction (anaphylaxis) - Persistent mydriasis

When using Mydriasert, clinicians should observe several precautions to minimize risk and ensure optimal efficacy. - Assess ocular history: verify absence of narrow-angle glaucoma before administration. - Monitor intra‑ocular pressure: check pressure before and after dilation in at‑risk patients. - Avoid use in patients with known hypersensitivity to phenylephrine, tropicamide or any excipients. - Limit exposure: use the minimal effective volume and avoid repeated dosing within 24 hours. - Store at room temperature: keep the solution below 25 °C in the original container, protected from light and moisture.

Mydriasert can interact with other ophthalmic or systemic agents; awareness of these interactions helps prevent adverse outcomes. Major Interactions (Avoid): - Systemic α‑adrenergic agonists (e.g., pseudoephedrine) may exacerbate hypertension. - Anticholinergic drugs (e.g., atropine) can cause excessive mydriasis and cycloplegia. - Monoamine oxidase inhibitors: increased risk of hypertensive crisis when combined with phenylephrine. Moderate Interactions (Monitor Closely): - Topical beta‑blockers: may mask phenylephrine‑induced tachycardia. - Carbonic anhydrase inhibitors: monitor intra‑ocular pressure changes. - Other mydriatic agents: avoid concurrent use to prevent over‑dilation.